Intercept Pharmaceuticals | سود ناخالص در فروش



سود ناخالص در فروش تغییر دادن تاریخ
Acadia Pharmaceuticals USD 256.99M 13.15M 2025-09
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 22.21M 28.15M 2025-09
Amgen USD 6.48B 307M 2025-09
Arrowhead Research USD 256.47M 228.7M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Biogen USD 1.65B 34.6M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Eli Lilly USD 14.59B 1.48B 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Esperion Therapeutics USD -29.52M 32.4M 2024-09
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Incyte USD 1.39B 118.68M 2025-12
Ionis Pharmaceuticals USD 155M 293M 2025-09
Moderna USD 226M 583M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.82B 695M 2025-09
PTC Therapeutics USD 187.69M 24.3M 2025-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sarepta Therapeutics USD 247.9M 209.96M 2025-09
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12


Intercept Pharmaceuticals سود ناخالص در فروش - ارزش های فعلی، داده های تاریخی، پیش بینی، آمار، نمودار و تقویم اقتصادی - Feb 2026.